全文获取类型
收费全文 | 7049篇 |
免费 | 587篇 |
国内免费 | 371篇 |
专业分类
耳鼻咽喉 | 117篇 |
儿科学 | 533篇 |
妇产科学 | 171篇 |
基础医学 | 414篇 |
口腔科学 | 63篇 |
临床医学 | 728篇 |
内科学 | 1475篇 |
皮肤病学 | 101篇 |
神经病学 | 54篇 |
特种医学 | 401篇 |
外国民族医学 | 3篇 |
外科学 | 1850篇 |
综合类 | 567篇 |
预防医学 | 166篇 |
眼科学 | 37篇 |
药学 | 304篇 |
中国医学 | 44篇 |
肿瘤学 | 979篇 |
出版年
2024年 | 18篇 |
2023年 | 110篇 |
2022年 | 245篇 |
2021年 | 317篇 |
2020年 | 254篇 |
2019年 | 263篇 |
2018年 | 246篇 |
2017年 | 233篇 |
2016年 | 305篇 |
2015年 | 284篇 |
2014年 | 409篇 |
2013年 | 465篇 |
2012年 | 375篇 |
2011年 | 393篇 |
2010年 | 332篇 |
2009年 | 355篇 |
2008年 | 377篇 |
2007年 | 385篇 |
2006年 | 381篇 |
2005年 | 277篇 |
2004年 | 235篇 |
2003年 | 185篇 |
2002年 | 159篇 |
2001年 | 160篇 |
2000年 | 124篇 |
1999年 | 91篇 |
1998年 | 116篇 |
1997年 | 104篇 |
1996年 | 77篇 |
1995年 | 73篇 |
1994年 | 70篇 |
1993年 | 48篇 |
1992年 | 49篇 |
1991年 | 48篇 |
1990年 | 52篇 |
1989年 | 31篇 |
1988年 | 49篇 |
1987年 | 33篇 |
1986年 | 38篇 |
1985年 | 28篇 |
1984年 | 26篇 |
1983年 | 18篇 |
1982年 | 28篇 |
1981年 | 33篇 |
1980年 | 19篇 |
1979年 | 24篇 |
1978年 | 15篇 |
1977年 | 16篇 |
1976年 | 11篇 |
1975年 | 8篇 |
排序方式: 共有8007条查询结果,搜索用时 15 毫秒
41.
42.
Elevated thrombin-antithrombin III complex concentrations in patients with gynaecological malignancy
Summary In patients with malignant tumors a high incidence of haemostatic disorders occurs. The reaction of thrombin with its major inhibitor antithrombin III (AT III) leads to the formation of a stable complex, which represents a sensitive marker for the activation of intravascular coagulation. In 153 patients suffering from different kinds of gynaecological malignancy thrombin-antithrombin III-complex (TAT) levels were measured. In 21 cases the course of the disease was studied. Of 153 patients with gynaecological malignancy 102 (67%) showed TAT plasma concentrations above the normal range before therapy. Seven patients with elevated TAT levels before treatment showed a decrease of TAT concentrations to the normal range when no evidence of disease was obvious. In 5 cases TAT levels were in the normal range before and after successful therapy. 4 patients with tumor progression and 5 patients with tumor recurrence showed an increase of TAT levels. The TAT plasma concentrations correlated with the presence or absence of the tumor. Measurement of TAT plasma concentrations in gynaecologic malignancies can detect any thromboembolic risk for the patient and in addition can reveal information about the course of the disease.Abbreviations Thrombin-Antithrombin III Komplex
(TAT)
- Antithrombin III
(AT III) 相似文献
43.
本文旨在探讨盆腔恶性肿瘤的介入性治疗问题。对45例患有盆腔恶性肿瘤的患者,采用Seldinger法,经双侧股动脉插管,先端选择性导入对侧髂内动脉;或一侧导入肠系膜下动脉,另侧导入髂内动脉,留置导管12小时,使用突击剂量持续灌注化疗药物。并经手术、B超、CT、内窥镜及指检等方法进行化疗前后的对比观察。结果:其中病灶消失持续1个月以上者9例、病灶缩小50%以上并持续超过一个月者23例、缩小不足50%且增大未达25%者9例、增大超过25%以上者4例,总有效率为71.1%。10例患者出现了脱发及皮肤色素沉着,1例患者出现下肢动脉栓塞,10例出现了不同程度的消化道反应等。结论:本法损伤小,操作简便安全,可多次重复术式:选择性强,药效持久均衡且毒副作用小;可提高手术切除率,也为不能手术的癌肿提供一种较理想的治疗手段。 相似文献
44.
Hypercalcemia in breast cancer 总被引:1,自引:0,他引:1
G. Francini R. Petrioli E. Maioli S. Gonnelli S. Marsili A. Aquino S. Bruni 《Clinical & experimental metastasis》1993,11(5):359-367
Hypercalcemia is relatively frequent in malignancy with or without osteolytic bone metastases. It is thought that neoplastic cells may secrete substances which not only stimulate osteoclastic activity but are also capable of modifying the absorption, excretion, and resorption of calcium and phosphate ions. Since 1987, we have studied 24 breast cancer patients with hypercalcemia (22 with bone metastases and two without). The group of 22 patients with bone metastases were divided into two subgroups. The first consisted of 10 patients with high serum levels of humoral factors, such as parathyroid hormone-related protein (PTHrP), and/or prostaglandin E2 (PGE2) and/or interleukin 1 (IL-1), and high levels of bone markers, such as alkaline phosphatase, bone Gla protein and urinary hydroxyproline. The second subgroup consisted of 12 patients with high levels of bone markers alone. Bone histologic analysis showed an osteoclastic activation surrounding metastatic tumor tissue in six out of 10 patients of the first subgroup, while an evident osteolysis caused by the tumor cells was noted in seven out of 12 patients of the second subgroup. The two patients without bone metastases showed normal biochemistry and bone histologic examination. The authors, having tried to explain the pathogenesis of hypercalcemia, emphasize the importance of humoral factors secreted by tumor cells as a direct or indirect cause of hypercalcemia. The origin of hypercalcemia remains unclear in two patients without bone metastases. 相似文献
45.
Corticosteroid therapy in biliary atresia 总被引:4,自引:0,他引:4
Sixteen patients with biliary atresia had 44 steroid courses for treatment of cholangitis or diminution of bile flow following Kasai hepatic portoenterostomy operations. A "blast" type (high dose/short duration) steroid administration was employed to potentiate the choleretic and anti-inflammatory effect. There was a significant augmentation of bile flow and a reduction in maximum temperature, serum bilirubin, and alkaline phosphatase. 相似文献
46.
皮下通道型胆囊肝胆管成形术治疗肝胆管结石 和胆管狭窄的临床研究 总被引:2,自引:1,他引:1
目的:总结皮下通道型胆囊肝胆管成形术的临床效果。方法:统计了1994年以来我院76例行STHG手术患者的适应症、临床效果及术后早期并发症。并选择同期实施的125 列行传统胆肠吻合(CJ)的患者进行对照。结果:STHG的手术适应症与传统胆肠吻合基本相同;STHG组患者的手术时间、住院时间、术中出血量明显少于CJ组,术后恢复良好,仅2例次并发症。结论;该术式既保存了胆囊及Oddi括约肌功能,又保证了胆汁的生理流向;防止了肠液的反,所以避免了消化功能紊乱,防止了反 流性胆管炎,对患者的影响小,是一种较为理想的治疗肝胆管结石和肝门胆管狭窄的术式。 相似文献
47.
Ursula Thiem Veronika Buxhofer-Ausch Wolfgang Kranewitter Gerald Webersinke Wolfgang Enkner Daniel Cejka 《American journal of transplantation》2021,21(1):405-409
Active malignancy is an absolute contraindication to kidney transplantation. As for chronic myeloid leukemia (CML), a Philadelphia chromosome-positive myeloproliferative neoplasm, the introduction of tyrosine kinase inhibitors has transformed CML from a lethal into a manageable chronic disease with a close-to-normal life expectancy. To date it is unknown whether kidney transplantation can be safely performed in patients with pre-existing CML. We describe the clinical course of a 57-year-old male patient with chronic kidney disease caused by reflux nephropathy. This patient had undergone first kidney transplantation 20 years earlier and had again been on chronic hemodialysis for 6 years when CML was diagnosed. First-line therapy with 400 mg imatinib daily was well tolerated and induced an optimal cytogenetic and molecular response 3 months after initiation. One and a half years after CML diagnosis, a second kidney transplantation from a deceased donor was performed. Immunosuppression included basiliximab, tacrolimus, mycophenolate mofetil, and corticosteroids. Currently, 2 years posttransplant, renal allograft function is stable (serum creatinine 1.09 mg/dL, estimated glomerular filtration rate 75 mL/min per 1.73 m2), and CML remains in deep molecular remission with imatinib. Imatinib-treated CML in deep molecular remission could be regarded as inactive malignancy and may therefore not be viewed as an absolute contraindication to kidney transplantation. 相似文献
48.
Jonathan Kentley Rina Allawh Swati Rao Alden Doyle Amar Ahmad Kumar Nadhan Charlotte Proby Catherine A. Harwood Christina L. Chung 《American journal of transplantation》2021,21(3):1215-1226
Organ transplant recipients (OTRs) are at increased risk of cutaneous malignancy. Skin disorders in OTRs of color (OTRoC) have rarely been systematically assessed. We aimed to ascertain the burden of skin disease encountered in OTRoC by prospectively collecting data from OTRs attending 2 posttransplant skin surveillance clinics: 1 in London, UK and 1 in Philadelphia, USA. Retrospective review of all dermatological diagnoses was performed. Data from 1766 OTRs were analyzed: 1024 (58%) white, 376 (21%) black, 261 (15%) Asian, 57 (3%) Middle Eastern/Mediterranean (ME/M), and 48 (2.7%) Hispanic; and 1128 (64%) male. Viral infections affected 45.1% of OTRs, and were more common in white and ME/M patients (P < .001). Fungal infections affected 28.1% and were more common in ME/M patients (P < .001). Inflammatory skin disease affected 24.5%, and was most common in black patients (P < .001). In addition, 26.4% of patients developed skin cancer. There was an increased risk of skin cancer in white vs nonwhite OTRs (HR 4.4, 95% CI 3.5-5.7, P < .001): keratinocyte cancers were more common in white OTRs (P < .001) and Kaposi sarcoma was more common in black OTRs (P < .001). These data support the need for programs that promote targeted dermatology surveillance for all OTRs, regardless of race/ethnicity or country of origin. 相似文献
49.
David P. Al-Adra Laura Hammel John Roberts E. Steve Woodle Deborah Levine Didier Mandelbrot Elizabeth Verna Jayme Locke Jonathan D'Cunha Maryjane Farr Deirdre Sawinski Piyush K. Agarwal Jennifer Plichta Sandhya Pruthi Deborah Farr Richard Carvajal John Walker Fiona Zwald Thomas Habermann Morie Gertz Philip Bierman Don S. Dizon Carrie Langstraat Talal Al-Qaoud Scott Eggener John P. Richgels George J. Chang Cristina Geltzeiler Gonzalo Sapisochin Rocco Ricciardi Alexander S. Krupnick Cassie Kennedy Nisha Mohindra David P. Foley Kymberly D. Watt 《American journal of transplantation》2021,21(2):460-474
Patients undergoing evaluation for solid organ transplantation (SOT) often have a history of malignancy. Although the cancer has been treated in these patients, the benefits of transplantation need to be balanced against the risk of tumor recurrence, especially in the setting of immunosuppression. Prior guidelines of when to transplant patients with a prior treated malignancy do not take in to account current staging, disease biology, or advances in cancer treatments. To develop contemporary recommendations, the American Society of Transplantation held a consensus workshop to perform a comprehensive review of current literature regarding cancer therapies, cancer stage-specific prognosis, the kinetics of cancer recurrence, and the limited data on the effects of immunosuppression on cancer-specific outcomes. This document contains prognosis based on contemporary treatment and transplant recommendations for breast, colorectal, anal, urological, gynecological, and nonsmall cell lung cancers. This conference and consensus documents aim to provide recommendations to assist in the evaluation of patients for SOT given a history of a pretransplant malignancy. 相似文献
50.
Christina D. Mejia Adam M. Frank Pooja Singh Anju Yadav 《American journal of transplantation》2021,21(3):1322-1325
Immune checkpoint inhibitors (ICPIs) are monoclonal antibodies against inhibitory receptors on T cells resulting in anticancer activity. In kidney transplant (KT) recipients, ICPI use has been associated with acute allograft rejection. In failed allografts, however, the effects of ICPIs are unknown. We present a case of a 66-year-old man with a history of diabetes, renal cell cancer, left native nephrectomy, and end-stage kidney disease. He received a deceased donor KT which failed after 6 years due to biopsy-proven recurrent diabetic nephrosclerosis. He was started on hemodialysis and his immunosuppression was gradually weaned off. A year later, he was diagnosed with renal cell cancer in his right native kidney requiring nephrectomy. He later developed metastasis and was started on combination ICPIs. He developed hematuria, allograft pain, and malaise consistent with graft intolerance syndrome 28 days after starting ICPIs. Urine culture and cystoscopy were normal. A computed tomography scan of his abdomen revealed an enlarged allograft with patchy enhancement. After a multidisciplinary discussion, he underwent transplant nephrectomy. Histopathology showed chronic active T cell–mediated rejection. As ICPI use becomes prevalent, practitioners need to be aware of its potential complications among KT recipients both with functioning and failed allografts. 相似文献